NCT04764656View on ClinicalTrials.gov

Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal

TerminatedOBSERVATIONAL
Enrollment

81

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

February 16, 2024

Study Completion Date

February 16, 2024

Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
DRUG

Brolucizumab

There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.

Trial Locations (11)

00-024

Novartis Investigative Site, Funchal

2410-187

Novartis Investigative Site, Leiria

1050-078

Novartis Investigative Site, Lisbon

1200-473

Novartis Investigative Site, Lisbon

1500-473

Novartis Investigative Site, Lisbon

1600-209

Novartis Investigative Site, Lisbon

1649-020

Novartis Investigative Site, Lisbon

1990-196

Novartis Investigative Site, Lisbon

4050-115

Novartis Investigative Site, Porto

4520 211

Novartis Investigative Site, Santa Maria da Feira

2300-625

Novartis Investigative Site, Tomar

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY